BRPI0413755A - inibidores de catepsina s - Google Patents

inibidores de catepsina s

Info

Publication number
BRPI0413755A
BRPI0413755A BRPI0413755-8A BRPI0413755A BRPI0413755A BR PI0413755 A BRPI0413755 A BR PI0413755A BR PI0413755 A BRPI0413755 A BR PI0413755A BR PI0413755 A BRPI0413755 A BR PI0413755A
Authority
BR
Brazil
Prior art keywords
cathepsin
cathepsin inhibitors
present
selective inhibition
inhibitors
Prior art date
Application number
BRPI0413755-8A
Other languages
English (en)
Inventor
Hong Liu
Phillip B Alper
Donald S Karanewsky
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of BRPI0413755A publication Critical patent/BRPI0413755A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

"INIBIDORES DE CATEPSINA S". A presente invenção fornece compostos, composições e métodos para a inibição seletiva da catepsina S. Em um aspecto preferido, a catepsina E é seletivamente inibida na presença de pelo menos uma outra isozima do tipo catepsina. A presente invenção também fornece métodos para o tratamento de um estado patológico em um indivíduo pela inibição seletiva da catepsina S.
BRPI0413755-8A 2003-08-20 2004-08-19 inibidores de catepsina s BRPI0413755A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49685803P 2003-08-20 2003-08-20
US10/922,362 US7256207B2 (en) 2003-08-20 2004-08-18 Inhibitors of cathepsin S
PCT/US2004/027316 WO2005018568A2 (en) 2003-08-20 2004-08-19 Inhibitors of cathepsin s

Publications (1)

Publication Number Publication Date
BRPI0413755A true BRPI0413755A (pt) 2006-10-31

Family

ID=34221426

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413755-8A BRPI0413755A (pt) 2003-08-20 2004-08-19 inibidores de catepsina s

Country Status (8)

Country Link
US (2) US7256207B2 (pt)
EP (1) EP1658274A4 (pt)
JP (1) JP2007502844A (pt)
AU (1) AU2004266151B2 (pt)
BR (1) BRPI0413755A (pt)
CA (1) CA2534489A1 (pt)
MX (1) MXPA06001888A (pt)
WO (1) WO2005018568A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7256207B2 (en) * 2003-08-20 2007-08-14 Irm Llc Inhibitors of cathepsin S
TWI389897B (zh) 2005-02-22 2013-03-21 Chugai Pharmaceutical Co Ltd 1- (2H) -isoquinolinone derivatives
US7751835B2 (en) * 2005-10-04 2010-07-06 Airvana, Inc. Non-circular paging areas
WO2011069298A1 (en) 2009-12-11 2011-06-16 F. Hoffmann-La Roche Ag Novel cyclopropane indolinone derivatives
GB2476823B (en) 2010-01-11 2012-05-02 Subsea 7 Contracting Uk Ltd Improvements relating to abandonment and recovery of pipelines
CA3127128A1 (en) * 2019-01-22 2020-07-30 Adverio Pharma Gmbh Process for manufacturing 4-(2,2,3,3-tetrafluoropropyl)morpholine
WO2020201572A1 (en) 2019-04-05 2020-10-08 Université De Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499295A (en) 1983-05-09 1985-02-12 G. D. Searle & Co. Protease inhibitors
US5374623A (en) 1992-08-20 1994-12-20 Prototek, Inc. Cysteine protease inhibitors effective for in vivo use
CN1078204C (zh) 1993-04-28 2002-01-23 久美蓝化学工业株式会社 氨基酸酰胺衍生物及其杀真菌的用途和制备方法
US5648514A (en) 1994-12-29 1997-07-15 Allergan Substituted acetylenes having retinoid-like biological activity
US5691368A (en) 1995-01-11 1997-11-25 Hoechst Marion Roussel, Inc. Substituted oxazolidine calpain and/or cathepsin B inhibitors
US5849711A (en) 1995-06-06 1998-12-15 Athena Neurosciences, Inc. Cathepsin and methods and compositions for inhibition thereof
TW438591B (en) 1995-06-07 2001-06-07 Arris Pharm Corp Reversible cysteine protease inhibitors
EP0804180A4 (en) 1995-10-30 2001-09-05 Smithkline Beecham Corp METHOD FOR INHIBITING CATHEPS
SK56798A3 (en) 1995-10-30 1998-12-02 Smithkline Beecham Corp Protease inhibitors, pharmaceutical composition containing them and their use
DE19610784A1 (de) * 1996-03-19 1997-09-25 Hoechst Ag Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung
US5840733A (en) 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
US5916887A (en) 1996-09-23 1999-06-29 National Research Council Of Canada 4-substituted-3-(2-amino-2-cycloalkyl methyl)-acetamido azetidin-2-one derivatives as cysteine proteinase regulators
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
JP2001525809A (ja) 1997-05-08 2001-12-11 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害剤
GB9723407D0 (en) 1997-11-05 1998-01-07 Ciba Geigy Ag Organic compounds
GB9903548D0 (en) 1999-02-16 1999-04-07 Novartis Ag Organic compounds
JP2002538151A (ja) 1999-03-02 2002-11-12 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド カテプシンの可逆的インヒビターとして有用な化合物
EP1161415B1 (en) 1999-03-15 2005-07-13 Axys Pharmaceuticals, Inc. N-cyanomethylamides as protease inhibitors
WO2001009110A1 (en) 1999-07-30 2001-02-08 Boehringer Ingelheim Pharmaceuticals, Inc. Novel succinate derivative compounds useful as cysteine protease inhibitors
HK1048807A1 (zh) 1999-09-13 2003-04-17 贝林格尔‧英格海姆药物公司 用作半胱氨酸蛋白酶的可逆抑制剂的新颖螺旋杂环化合物
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
NZ521028A (en) * 2000-03-16 2004-07-30 F Carboxylic acid derivatives as IP antagonists
NZ524192A (en) 2000-08-14 2005-02-25 Ortho Mcneil Pharm Inc Substituted pyrazoles
RU2317988C2 (ru) 2000-08-14 2008-02-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы, фармацевтическая композиция на их основе, применение фармацевтической композиции и способ ингибирования активности катепсина s
EP1309591B1 (en) 2000-08-14 2007-01-24 Ortho-McNeil Pharmaceutical, Inc. Substituted pyrazoles
IL156577A0 (en) 2000-12-22 2004-01-04 Axys Pharm Inc Selective cathepsin s inhibitors and pharmaceutical compositions containing the same
WO2002070517A2 (en) 2001-03-02 2002-09-12 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
US7012075B2 (en) 2001-03-02 2006-03-14 Merck & Co., Inc. Cathepsin cysteine protease inhibitors
WO2002070519A1 (en) 2001-03-05 2002-09-12 Axys Pharmaceuticals, Inc. Monobactams as cathepsin k inhibitors
WO2003013518A1 (en) 2001-08-03 2003-02-20 Smithkline Beecham Corporation Alpha-ketoamide derivatives as cathepsin k inhibitors
US20030144234A1 (en) 2001-08-30 2003-07-31 Buxton Francis Paul Methods for the treatment of chronic pain and compositions therefor
WO2003031437A1 (en) * 2001-10-09 2003-04-17 Smithkline Beecham Corporation Propylcarbamate derivatives as inhibitors of serine and cysteine proteases
WO2004000838A1 (en) 2002-06-24 2003-12-31 Axys Pharmaceuticals, Inc. Peptidic compounds as cysteine protease inhibitors
US7256207B2 (en) * 2003-08-20 2007-08-14 Irm Llc Inhibitors of cathepsin S

Also Published As

Publication number Publication date
CA2534489A1 (en) 2005-03-03
US20070259873A1 (en) 2007-11-08
WO2005018568A2 (en) 2005-03-03
WO2005018568A3 (en) 2005-09-09
EP1658274A4 (en) 2008-11-12
US7507755B2 (en) 2009-03-24
US20050107368A1 (en) 2005-05-19
AU2004266151A1 (en) 2005-03-03
JP2007502844A (ja) 2007-02-15
MXPA06001888A (es) 2006-05-31
US7256207B2 (en) 2007-08-14
EP1658274A2 (en) 2006-05-24
AU2004266151B2 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
BRPI0415960A (pt) composto ou um sal do mesmo, pró-droga de um composto, agente farmacêutico, inibidor de peptidase, composto ou um sal do mesmo, pró-droga de um composto, agente farmacêutico, inibidor de peptidase, uso de um composto,e, método para produzir um composto
BR0115411A (pt) Combinações sinergìsticas compreendendo um inibidor de renina para doenças cardiovasculares
TW200505829A (en) Protease inhibitors for coronaviruses and sars-cov and the use thereof
TNSN07111A1 (en) Preparation and use of biphenyl-4-yl- carbonylamino acid derivatives for the treatment of obesity.
PT2275097T (pt) Composições que incluem canabinoides para tratamento de náuseas, vómitos, émese, enjoo ou condições idênticas
MXPA04004347A (es) Nuevos fotoindicadores difuncionales.
MX2009000657A (es) Composiciones y metodos para el tratamiento de mucositis.
BRPI0207215B8 (pt) Derivados de pirazolopirimidinona tendo ação de inibição de pde7
PT1587821E (pt) Composições e métodos para estabilização da transtirretina e inibição do enrolamento incorrecto da transtirretina
AR020345A1 (es) Pirazol-carboxanilidas, procedimiento para su obtencion, composiciones, empleo de dichos compuestos y procedimiento para la lucha contra microorganismos indeseables, y procedimiento para la obtencion de dichas composiciones.
BR0313282A (pt) Composições de inibidor seletivo de ciclooxigenase-2 e um inibidor de anidrase carbÈnica para o tratamento de neoplasia
DK1370260T3 (da) Azoler, som malonyl-coa-decarboxylaseinhibitorer anvendelige som mataboliske modulatorer
TW200716183A (en) Parakeratosis inhibitor, pore-contracting agent and external composition for skin
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas
WO2004084842A3 (en) Inhibitors of cathepsin s
WO2007059154A3 (en) Treatment of cancers with acquired resistance to kit inhibitors
BRPI0413755A (pt) inibidores de catepsina s
ATE443044T1 (de) Tace inhibitoren
BRPI0409690A (pt) associação terapêutica de um inibidor de cox-2 e um inibidor de aromatase
BRPI0418854A (pt) composições herbáceas
BRPI0415824A (pt) inibidores de catepsina s
IN2015DN03331A (pt)
WO2004112709A3 (en) Inhibitors of cathepsin s

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.